# Provider Summary — Metabolic dysfunction + dysautonomia — draft

_Provider-facing clinical summary. Source-attributed. Not patient-facing._

- **Patient:** DEMO-006
- **Provider:** dr_demo
- **Plan status:** signed_off
- **Assessment date:** —
- **Signed off:** 2026-06-14T00:42:53.888+00:00

## Clinical context (snapshot)
- Primary phenotype: metabolic_dysfunction
- Secondary phenotype: dysautonomia
- Recovery stage: improving
- Safety: Moderate Review Priority — critical 0, high 0
- Outcomes: clinical improvement 62, functional 64

## Components (1)

### 1. Tesamorelin (peptide)
- Provider instruction: As directed by your provider.
- Monitoring: Monitor tolerance.
- Safety: Contact the clinic with concerns.

_Provider-only. Generated from the signed-off plan; original sources remain the source of truth._